Ratings Ray Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
13,400 ^KRW	-0.59%		-2.05%	-41.36%

03-27	Ray Co., Ltd. announced that it has received KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.	CI
03-25	Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RAY CO., LTD.	-41.36%	148M		-
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	-3.25%	15.01B		-
IRAY TECHNOLOGY COMPANY LIMITED	-38.91%	2.8B		C-
SONOSCAPE MEDICAL CORP.	-12.68%	2.45B		-
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	-12.18%	1.46B	-	-
CORETAG, INC.	-.--%	1.12B	-	-
NANO-X IMAGING LTD.	+43.80%	518M		-
GUERBET	+92.56%	505M		B+
DETECTION TECHNOLOGY OYJ	+14.23%	245M		C
DRTECH CORPORATION	-19.37%	183M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality